Q4 2025 MannKind Corp Earnings Call Transcript

Feb 26, 2026 / 02:00 PM GMT

Release Date Price: €2.7 (-10.88%)

Transcript 10-K8-K

Key Points

Positve

MannKind Corp (MNKD) reported a record quarterly revenue of $112 million in Q4 2025, reflecting a 46% increase from the prior year.
The company completed the acquisition of SC Pharmaceuticals, enhancing its cardio metabolic franchise.
MannKind Corp (MNKD) has a diversified commercial stage organization with four FDA-approved products, reducing dependency on a single revenue stream.
The company anticipates a revenue run rate of over $450 million in 2026, driven by strategic investments and product launches.
MannKind Corp (MNKD) is advancing its clinical stage program, Mankind 201, which has blockbuster potential in treating idiopathic pulmonary fibrosis (IPF).

Negative

The company reported a GAAP net loss of $15.9 million for Q4 2025.
There is potential variability or decline in Tyvaso DPI sales, which could impact MannKind Corp (MNKD)'s financials despite a dampened effect due to the royalty structure.
The gross margin may decline slightly in 2026 before improving significantly with the launch of the auto-injector.
MannKind Corp (MNKD) faces competition in the pulmonary arterial hypertension (PAH) market, which could affect its market share.
The company is investing heavily in its pipeline and commercial infrastructure, which could strain financial resources if expected growth does not materialize.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MNKD.OQ - MannKind Corp
Q4 2025 MannKind Corp Earnings Call
Feb 26, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Mankind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026 and will be available for replay on the Mankind Corporation website shortly after this call and for approximately 90 days. This call will contain 4 forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company's risk factors, please see the Form 10k for the annual period ended December 31, 2025, the earnings release, and the slides prepared for this presentation.

Joining us today from mankind are Chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.